Ten post jest także dostępny w języku: polski
Ryvu Therapeutics S.A., one of Europe’s largest innovative biotechnology companies active in the discovery and development of new oncology therapies, has announced that Vatnak Vat-Ho is joining the company as Chief Business Officer.
Ryvu will gain knowledge and experience from Vatnak Vat-Ho
Vatnak Vat-Ho holds a bachelor’s degree in biology from Harvard University. Ryvu‘s new Chief Business Officer also graduated from the Leonard N. Stern School of Business at New York University with a MBA. In terms of professional experience, Vatnak Vat-Ho has worked for nearly twenty years in the areas of pharmaceuticals, biotechnology and capital markets. For the first 10 years of his career he worked in various investment banks and global equity funds. He then began his career in the pharmaceutical and biotechnology industries.
Ryvu said in its announcement that he worked at Pfizer for eight years, where he held several roles, including Senior Director/Business Development and Collaboration Team Leader for Strategy, Business Development and Collaboration. Prior to joining Ryvu, Vatnak Vat-Ho held the position of Vice President of Business Development at Affimed Inc. where he was responsible for leading partnering activities for both preclinical and clinical stage projects. At the aforementioned company, he also served as Collaboration Manager.
In his role as Ryvu’s Chief Business Officer, Vatnak Vat-Ho is to be responsible for a wide range of corporate and business activities, including the company’s strategic market positioning, partnering discussions, initiating key scientific collaboration projects and investor relations.